ArticleBMC medicine2018
The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Healthcare resource use and costs of varicella and its complications: A systematic literature review.Human vaccines & immunotherapeutics · 2023Pooled it
- Pooled it
- Incorporating human dynamic populations in models of infectious disease transmission: a systematic review.BMC infectious diseases · 2022Pooled it
- Quantitative study of the knowledge, attitudes, and practices (KAP) towards herpes zoster (HZ) and HZ vaccination: Survey findings from a multi-country study in Asia (ZOASIS).Human vaccines & immunotherapeutics · 2026Article
- The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses.Infectious diseases and therapy · 2026Article
- Article
- Modeling the clinical and economic impact of universal varicella vaccination in Belgium with dynamic population.PLOS global public health · 2026Article
- Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50 years in Zhejiang province, China.Frontiers in public health · 2025Article
- Knowledge, attitude, and practice toward herpes zoster (HZ) and HZ vaccination: Concept elicitation findings from a multi-country study in the Asia Pacific.Human vaccines & immunotherapeutics · 2024Article
- Exploring the impact of population ageing on the spread of emerging respiratory infections and the associated burden of mortality.BMC infectious diseases · 2023Article
- Article
- Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.Therapeutic advances in vaccines and immunotherapy · 2022Review
- Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.Vaccine · 2021Article
- Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.PloS one · 2021Article
- Hospitalization for acute cerebellitis in children affected by varicella: how much does it cost?Italian journal of pediatrics · 2020Article
- Spatiotemporal Epidemiology of Varicella in Chongqing, China, 2014-2018.International journal of environmental research and public health · 2020Article
- Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study.Medical & biological engineering & computing · 2019Article
- Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe present study aims to evaluate the cost-effectiveness of the newly introduced varicella and herpes zoster (HZ) vaccination programmes in Italy. The appropriateness of the introduction of the varicella vaccine is highly debated because of concerns about the consequences on HZ epidemiology and the expected increase in the number of severe cases in case of suboptimal coverage levels.
methodsWe performed a cost-utility analysis based on a stochastic individual-based model that considers realistic demographic processes and two different underlying mechanisms of exogenous boosting (temporary and progressive immunity). Routine varicella vaccination is given with a two-dose schedule (15 months, 5-6 years). The HZ vaccine is offered to the elderly (65 years), either alone or in combination with an initial catch-up campaign (66-75 years). The main outcome measures are averted cases and deaths, costs per quality-adjusted life years gained, incremental cost-effectiveness ratios, and net monetary benefits associated with the different vaccination policies.
resultsDemographic processes have contributed to shaping varicella and HZ epidemiology over the years, decreasing varicella circulation and increasing the incidence of HZ. The recent introduction of varicella vaccination in Italy is expected to produce an enduring reduction in varicella incidence and, indirectly, a further increase of HZ incidence in the first decades, followed by a significant reduction in the long term. However, the concurrent introduction of routine HZ vaccination at 65 years of age is expected to mitigate this increase and, in the longer run, to reduce HZ burden to its minimum. From an economic perspective, all the considered policies are cost-effective, with the exception of varicella vaccination alone when considering a time horizon of 50 years. These results are robust to parameter uncertainties, to the two different hypotheses on the mechanism driving exogenous boosting, and to different demographic projection scenarios.
conclusionsThe recent introduction of a combined varicella and HZ vaccination programme in Italy will produce significant reductions in the burden of both diseases and is found to be a cost-effective policy. This programme will counterbalance the increasing trend of zoster incidence purely due to demographic processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.